Barclays
MRTX

Barclays’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Barclays’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-492,345
Closed -$28.9M – 5480
2023
Q4 		$28.9M Buy
492,345
+364,571
+285% +$20.5M 0.01% 908
2023
Q3 		$5.57M Buy
127,774
+23,903
+23% +$853K ﹤0.01% 1264
2023
Q2 		$3.75M Sell
103,871
-37,989
-27% -$1.57M ﹤0.01% 1514
2023
Q1 		$5.27M Sell
141,860
-86,565
-38% -$3.89M ﹤0.01% 1505
2022
Q4 		$10.3M Buy
228,425
+101,331
+80% +$6.56M ﹤0.01% 1187
2022
Q3 		$8.88M Buy
127,094
+115,181
+967% +$8.52M 0.01% 901
2022
Q2 		$800K Sell
11,913
-12,263
-51% -$780K ﹤0.01% 2526
2022
Q1 		$1.99M Sell
24,176
-8,294
-26% -$848K ﹤0.01% 1868
2021
Q4 		$4.76M Buy
32,470
+17,374
+115% +$2.7M ﹤0.01% 1740
2021
Q3 		$2.67M Sell
15,096
-14,994
-50% -$2.41M ﹤0.01% 2101
2021
Q2 		$4.86M Sell
30,090
-9,175
-23% -$1.47M ﹤0.01% 1598
2021
Q1 		$6.73M Buy
39,265
+936
+2% +$185K ﹤0.01% 1283
2020
Q4 		$8.42M Sell
38,329
-54,938
-59% -$11.9M ﹤0.01% 1235
2020
Q3 		$15.5M Buy
93,267
+5,272
+6% +$721K 0.01% 857
2020
Q2 		$10M Sell
87,995
-18,370
-17% -$1.78M 0.01% 960
2020
Q1 		$8.18M Buy
106,365
+48,194
+83% +$4.32M 0.01% 1120
2019
Q4 		$7.5M Buy
58,171
+36,799
+172% +$3.55M ﹤0.01% 1618
2019
Q3 		$1.67M Sell
21,372
-12,525
-37% -$1.18M ﹤0.01% 3096
2019
Q2 		$3.49M Sell
33,897
-19,462
-36% -$1.52M ﹤0.01% 2252
2019
Q1 		$3.91M Buy
53,359
+13,556
+34% +$922K ﹤0.01% 1871
2018
Q4 		$1.69M Buy
39,803
+24,300
+157% +$968K ﹤0.01% 2578
2018
Q3 		$730K Sell
15,503
-10,148
-40% -$565K ﹤0.01% 3939
2018
Q2 		$1.26M Sell
25,651
-14,549
-36% -$550K ﹤0.01% 3019
2018
Q1 		$1.23M Buy
40,200
+22,200
+123% +$616K ﹤0.01% 2970
2017
Q4 		$328K Buy
18,000
+5,500
+44% +$85.3K ﹤0.01% 4259
2017
Q3 		$146K Sell
12,500
-20,086
-62% -$116K ﹤0.01% 4664
2017
Q2 		$119K Buy
32,586
+26,204
+411% +$100K ﹤0.01% 4784
2017
Q1 		$33K Buy
6,382
+5,860
+1,123% +$32.1K ﹤0.01% 5564
2016
Q4 		$2K Buy
522
+234
+81% +$1.27K ﹤0.01% 6396
2016
Q3 		$2K Sell
288
-3,607
-93% -$19.2K ﹤0.01% 6290
2016
Q2 		$21K Buy
3,895
+3,131
+410% +$49.9K ﹤0.01% 5255
2016
Q1 		$16K Buy
764
+661
+642% +$14.8K ﹤0.01% 5317
2015
Q4 		$3K Buy
+103
New +$3.64K ﹤0.01% 5701
2015
Q3 		– Sell
-190
Closed -$6K – 7125
2015
Q2 		$6K Sell
190
-71
-27% -$2.09K ﹤0.01% 6379
2015
Q1 		$7K Sell
261
-322
-55% -$7.55K ﹤0.01% 6456
2014
Q4 		$10K Buy
583
+347
+147% +$5.85K ﹤0.01% 6727
2014
Q3 		$4K Buy
236
+79
+50% +$1.47K ﹤0.01% 7262
2014
Q2 		$3K Sell
157
-730
-82% -$14.1K ﹤0.01% 7314
2014
Q1 		$17K Buy
+887
New +$18.4K ﹤0.01% 6680

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Barclays's MRTX Position: Q1 2024 in Review

Barclays sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 492,345 shares — an estimated $28.9M sold.

Barclays first reported a position in MRTX in Q1 2014 and held it in 39 quarters. The position peaked at $28.9M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Barclays reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Barclays sold 492,345 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $28.9M.
  • Barclays first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2014 and held it in 39 quarters.
  • Barclays's Mirati Therapeutics, Inc. Common Stock position peaked at $28.9M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Barclays's 13F filing for Q1 2024, filed 15 May 2024.